# PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

> **NCT02918747** · PHASE2 · UNKNOWN · sponsor: **Hunan Cancer Hospital** · enrollment: 100 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** pegaspargase
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **RADIATION:** IMRT

## Key facts

- **NCT ID:** NCT02918747
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2021-09
- **Final completion:** 2021-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02918747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02918747, "PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02918747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*